Device companies spend differently from drug companies

We compared five large device companies with five large drug companies, using their latest reported (GAAP or IFRS) figures. The device firms are Medtronic, Stryker, Boston Scientific, Abbott, and Intuitive. The drug firms are Lilly, Merck, Roche, Pfizer, and AbbVie (see the companion pharma article).

Share of revenueDevice companiesDrug companies
Cost of sales31 to 44%17 to 30%
R&D6.5 to 13%15 to 24%
SG&A24 to 34%16 to 24%
Operating margin18 to 29%25 to 40% (where reported)

The pattern is consistent:

  • Manufacturing costs more. Device cost of sales is roughly a third of revenue or more, against 17 to 30% for drugs.
  • Selling costs more. SG&A, which covers sales representatives and clinical support in hospitals, is the largest spending line after cost of sales at every device company. At Medtronic, Stryker, and Boston Scientific it is above 30%.
  • R&D is much smaller. It is typically under 10% of revenue, about half the pharma level.

How to read the numbers. The device companies list cost of products sold before amortization of acquired intangibles, which is shown on its own line. Abbott’s figures cover the whole company, including diagnostics, nutrition, and established pharmaceuticals. Its medical devices segment had $21.4 billion of sales.

Five companies, five budgets

[Chart: Company earnings releases and 10-K filings (GAAP; Medtronic FY ended April 2026, others calendar 2025). AskDona calculations. See the live document for the chart.]

Company (revenue)Cost of salesR&DSG&AAmortizationOperating margin
Abbott, whole company ($44.3B)44%6.6%28%3.8%18%
Medtronic, FY26 ($36.4B)35%7.9%32%4.9%18%
Stryker ($25.1B)36%6.5%34%2.9%19.5%
Boston Scientific ($20.1B)31%10.2%34%4.5%18%
Intuitive ($10.1B)34%13.0%24%not separate29%

What the numbers show:

  • The sales and service model dominates. SG&A is about 4 to 5 times R&D at Medtronic, Stryker, and Abbott. Device sales typically rely on representatives and clinical specialists who support procedures, and on broad hospital contracting.
  • Higher R&D goes with higher growth bets. Boston Scientific (10.2%) and Intuitive (13.0%) spend the most on R&D as a share of revenue. Intuitive also has the lowest SG&A and the highest operating margin.
  • Deals leave amortization. Medtronic carries $1.8 billion of amortization and Boston Scientific $0.9 billion, from past acquisitions.
  • Margins cluster at about 18 to 20%. Intuitive is the exception at 29%.

Below the income statement: factories, deals, and shareholders

CompanyCapital spendingDividendsBuybacksAcquisitions (net cash) and notable deals
Abbott$2.2B$4.1B$0.9B$0.1B in 2025; Exact Sciences announced November 2025 (about $21B equity value), expected to close in Q2 2026
Medtronic (FY26)$1.9B$3.6B$1.0B$0.4B; CathWorks completed
Stryker$0.8B$1.3Bnone shown$5.0B; Inari Medical (about $4.9B)
Boston Scientific$0.9Bnonenone shown$1.6B across several companies; Penumbra and Valencia announced January 2026
Intuitive$0.5Bnone$2.3B (23% of revenue)small

Capital spending is modest at every company, 3 to 5% of revenue, compared with 12% at Eli Lilly.

Three capital allocation models:

  • Pay dividends (Medtronic, Abbott). Medtronic paid $3.6 billion in dividends, about 10% of revenue and nearly twice its capital spending.
  • Buy growth (Stryker, Boston Scientific, Abbott). Stryker spent $5.0 billion on acquisitions in 2025, more than its net earnings of $3.2 billion. Boston Scientific pays no dividend and puts its cash into deals. Abbott’s pending Exact Sciences deal, at about $21 billion, is several times its annual R&D.
  • Buy back stock (Intuitive). Intuitive pays no dividend but returned $2.3 billion through buybacks.

Our reading: in devices, acquisitions often stand in for internal R&D. Large companies buy start-ups once their products show results, which is one reason the R&D line looks small.

Using financial statements in AI and RAG

  1. Index the primary filing (earnings release or 10-K) and record the fiscal year end. Medtronic’s ends in April.
  2. Separate segment data from company totals, as with Abbott’s devices segment and J&J MedTech.
  3. Record how cost of sales treats amortization (included or shown separately).
  4. Add acquisition cash from the cash flow statement to R&D when comparing innovation spending.
  5. Calculate ratios from stored figures, not from summaries.

Common mistakes

  • Comparing calendar-year and April fiscal-year results without noting it.
  • Treating a diversified company’s totals as device-only.
  • Judging innovation by the R&D line alone and ignoring acquisitions.
  • Mixing GAAP and adjusted figures.

Checklist

  • Fiscal year and basis recorded
  • Segment and total figures separated
  • Amortization treatment noted
  • Acquisitions included in the innovation view
  • Ratios recalculated from source figures

How AskDona helps

AskDona reads the earnings releases and 10-Ks you load. It answers questions such as “how much did each competitor spend on R&D and acquisitions last year?” and shows the exact line and page behind each figure.

Run a sample financial statement evidence check

AskDona shows the evidence; your finance and strategy teams decide.

Editor’s note. This article is general information, not investment advice. Figures are reported GAAP figures from each company’s latest full-year earnings release and 10-K. Medtronic’s year ended in April 2026; the others are calendar 2025. Percentages are our calculations.

FAQ

How much do medical device companies spend on R&D? About 6.5 to 13% of revenue. Intuitive is at the top, Stryker at the bottom.

Why is SG&A so high in medtech? Devices are typically sold and supported in hospitals by sales and clinical teams. SG&A ran at 24 to 34% of revenue.

How does this compare with pharma? Drug companies spend about twice as much on R&D (15 to 24%) and less on cost of sales and SG&A.

Which device company spent most on acquisitions? Stryker, with $5.0 billion in 2025, mainly for Inari Medical. Abbott’s pending Exact Sciences deal is larger.

References

All pages opened and checked by October 30, 2026.

SourceWhat it supports
Medtronic: FY26 Q4 earnings release (SEC)Medtronic income statement and cash flow
Stryker: Q4 2025 earnings releaseStryker income statement
Stryker: 10-K cash flow (SEC)Stryker capex, dividends, acquisitions
MassDevice: Stryker completes InariInari deal value
Boston Scientific: Q4 2025 earnings release (SEC)Boston Scientific income statement
Boston Scientific: 10-K cash flow (SEC)Capex, acquisitions
Abbott: Q4 and full-year 2025 resultsAbbott income statement, segment sales
Abbott: 10-K cash flow (SEC)Capex, dividends, buybacks
Abbott: 10-K (SEC)Exact Sciences deal
Intuitive: Q4 2025 earnings release (SEC)Intuitive income statement
Intuitive: 10-K cash flow (SEC)Capex, buybacks